NASDAQ:HCWB HCW Biologics Q2 2025 Earnings Report $1.66 -0.15 (-8.29%) Closing price 04:00 PM EasternExtended Trading$1.75 +0.09 (+5.42%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast HCW Biologics EPS ResultsActual EPS-$40.74Consensus EPS $10.80Beat/MissMissed by -$51.54One Year Ago EPSN/AHCW Biologics Revenue ResultsActual Revenue$0.01 millionExpected Revenue$7.00 millionBeat/MissMissed by -$6.99 millionYoY Revenue GrowthN/AHCW Biologics Announcement DetailsQuarterQ2 2025Date8/18/2025TimeBefore Market OpensConference Call DateMonday, August 18, 2025Conference Call Time8:00AM ETUpcoming EarningsHCW Biologics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) HCW Biologics Earnings HeadlinesHCW Biologics Updates Special Meeting Proxy MaterialsSeptember 10, 2026 | tipranks.comHCW Biologics Taps Akron Biotech To Market HCW11-006 For CAR-T Cell ProductionSeptember 8, 2026 | rttnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 23 at 1:00 AM | The Oxford Club (Ad)HCW Biologics signs Akron Biotech distribution deal for CAR-T manufacturing reagentSeptember 8, 2026 | msn.comHCW Biologics Enters Exclusive Distribution Agreement with Akron Biotech for HCW11-006 Reagent CommercializationSeptember 8, 2026 | quiverquant.comQHCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T CellsSeptember 8, 2026 | globenewswire.comSee More HCW Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email. Email Address About HCW BiologicsHCW Biologics (NASDAQ:HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic, low-grade inflammation, including cancer and age-related conditions. The company’s approach is designed to restore immune balance by reducing harmful inflammation while enhancing the body’s ability to generate an effective immune response. HCW Biologics uses its proprietary Tissue-based Optimized Biologics Immunotherapy (TOBI™) platform to create engineered fusion-protein therapeutics. Its lead investigational product, HCW9218, is designed to combine immune-stimulating activity through the interleukin-15 pathway with inhibition of transforming growth factor beta, a signaling protein that can suppress immune responses. The company has evaluated HCW9218 in clinical studies involving oncology and other inflammation-related applications. HCW Biologics is headquartered in Miramar, Florida, and its programs are primarily in research and clinical development rather than commercial production. The company was founded by immunology researcher Hing Wong, who has served as its chief executive officer and has led the development of its biologics platform and therapeutic pipeline.View HCW Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
